FDA Approves Diacomit (stiripentol) for Seizures Associated with Dravet Syndrome

On August 20, 2018, the U.S. Food and Drug Administration (FDA) approved Diacomit (stiripentol) for seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam. Dravet syndrome is a rare genetic condition that...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news